AI
| Followers | 12 |
| Posts | 421 |
| Boards Moderated | 0 |
| Alias Born | 09/29/2010 |
Tuesday, October 17, 2017 11:45:41 PM
I note that certain activities late 2016 and early 2017 could possibility contribute to increase sales in 2nd half of 2017.
Partnership with Terumo for cardiac surgery use was announced Sept 12, 2016 for 6 European countries. On Dec 20, 2016 PR, Terumo launch sales into the 6 countries. They introduced the CytoSorb CPB Procedure Pack and have plans to introduce other kits. Success of this partnership could lead to future expansion. Along the same line as Frensius partnership, I'm thinking that there will be Terumo worldwide co-marketing agreement announcement soon. That includes partnering on the REFRESH II pivotal study. If this is the case, it would be nice to put the value of the study in the PR at $10-12 million since Dr Chan has let this information out a few times to really make the stock price pop.
Enrolling patients into the cardiac study should run faster than for sepsis.
Three year partnership with Fresenius in critical care use was announced Dec 16, 2014 for 6 European countries. They initiated sales in the 6 countries in June 2016. On January 9 2017, they extended the 6 countries to 2019 and expanded the co-marketing agreement worldwide. It is expected that the co-marketing will commence worldwide starting in the second half of 2017. As part of the deal, FMC agrees to make guaranteed minimum quarterly orders and payments, evaluable every one and a half years. CytoSorbents talked about running some sepsis trials next year. (You may recall that there is an ongoing dosing study in EU as well) I think they will partner with Fresenius to run a pivotal study in the USA to gain FDA approval for the next generation CytoSorb XL. There is possiblity that the study results from the very first sepsis study (in Germany) or data from the CytoSorb registry will be accepted for the pilot study. The pilot study is small and its focused is mainly on safety of the device before continuing on to the pivotal study. You may recall that CytoSorb was declined under the EAP program. They need to run a large study for use in sepsis to be approved by the FDA.
If the potential partnerships are along the same line as the Aferetica one that was announced last month where it is paid for by the partner and CytoSorbents just provide the CytoSorb devices, the company will be saving considerable money. The value of the partnerships really need to be emphasized in the PR for investors to understand and in turn drive the stock price higher. Savings of $10-12 million for a 300-500 patient study really needs to be tooted! For two studies, that's a total $20-24 million that some big partners would be paying out of their accounts because they believe in the success of CytoSorb.
Partnership with Terumo for cardiac surgery use was announced Sept 12, 2016 for 6 European countries. On Dec 20, 2016 PR, Terumo launch sales into the 6 countries. They introduced the CytoSorb CPB Procedure Pack and have plans to introduce other kits. Success of this partnership could lead to future expansion. Along the same line as Frensius partnership, I'm thinking that there will be Terumo worldwide co-marketing agreement announcement soon. That includes partnering on the REFRESH II pivotal study. If this is the case, it would be nice to put the value of the study in the PR at $10-12 million since Dr Chan has let this information out a few times to really make the stock price pop.
Enrolling patients into the cardiac study should run faster than for sepsis. Three year partnership with Fresenius in critical care use was announced Dec 16, 2014 for 6 European countries. They initiated sales in the 6 countries in June 2016. On January 9 2017, they extended the 6 countries to 2019 and expanded the co-marketing agreement worldwide. It is expected that the co-marketing will commence worldwide starting in the second half of 2017. As part of the deal, FMC agrees to make guaranteed minimum quarterly orders and payments, evaluable every one and a half years. CytoSorbents talked about running some sepsis trials next year. (You may recall that there is an ongoing dosing study in EU as well) I think they will partner with Fresenius to run a pivotal study in the USA to gain FDA approval for the next generation CytoSorb XL. There is possiblity that the study results from the very first sepsis study (in Germany) or data from the CytoSorb registry will be accepted for the pilot study. The pilot study is small and its focused is mainly on safety of the device before continuing on to the pivotal study. You may recall that CytoSorb was declined under the EAP program. They need to run a large study for use in sepsis to be approved by the FDA.
If the potential partnerships are along the same line as the Aferetica one that was announced last month where it is paid for by the partner and CytoSorbents just provide the CytoSorb devices, the company will be saving considerable money. The value of the partnerships really need to be emphasized in the PR for investors to understand and in turn drive the stock price higher. Savings of $10-12 million for a 300-500 patient study really needs to be tooted! For two studies, that's a total $20-24 million that some big partners would be paying out of their accounts because they believe in the success of CytoSorb.
